Ubs Group Ag Hutchmed (China) LTD Transaction History

Ubs Group Ag

$527 Billion
Q4 2024

A detailed history of Ubs Group Ag transactions in Hutchmed (China) LTD stock. As of the latest transaction made, Ubs Group Ag holds 377,728 shares of HCM stock, worth $5.21 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

377,728

Previous 103,638 264.47%

Holding current value

$5.21 Million

Previous $2.03 Million 168.66%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$14.25 - $21.35 $3.91 Million - $5.85 Million	274,090 Added 264.47%	377,728 $5.44 Million
Q3 2024 Nov 14, 2024	BUY	$16.03 - $20.31 $1.1 Million - $1.39 Million	68,636 Added 196.09%	103,638 $2.03 Million
Q2 2024 Aug 13, 2024	BUY	$16.36 - $21.78 $294,594 - $392,192	18,007 Added 105.95%	35,002 $599,000
Q1 2024 May 13, 2024	SELL	$12.08 - $18.56 $227,236 - $349,132	-18,811 Reduced 52.54%	16,995 $285,000
Q4 2023 Feb 09, 2024	SELL	$16.25 - $20.23 $152,620 - $190,000	-9,392 Reduced 20.78%	35,806 $648,000
Q3 2023 Nov 09, 2023	SELL	$11.85 - $16.95 $19,410 - $27,764	-1,638 Reduced 3.5%	45,198 $765,000
Q2 2023 Aug 11, 2023	SELL	$10.78 - $17.73 $118,709 - $195,242	-11,012 Reduced 19.04%	46,836 $562,000
Q1 2023 May 12, 2023	BUY	$13.02 - $19.87 $18,241 - $27,837	1,401 Added 2.48%	57,848 $753,000
Q4 2022 Feb 08, 2023	SELL	$7.65 - $15.51 $717,929 - $1.46 Million	-93,847 Reduced 62.44%	56,447 $834,000
Q3 2022 Nov 10, 2022	BUY	$8.63 - $15.52 $90,485 - $162,727	10,485 Added 7.5%	150,294 $1.33 Million
Q2 2022 Aug 10, 2022	SELL	$8.59 - $20.77 $113,241 - $273,810	-13,183 Reduced 8.62%	139,809 $1.77 Million
Q1 2022 May 16, 2022	SELL	$15.52 - $35.65 $30,310 - $69,624	-1,953 Reduced 1.26%	152,992 $2.9 Million
Q4 2021 Feb 14, 2022	BUY	$28.89 - $35.33 $185,473 - $226,818	6,420 Added 4.32%	154,945 $5.44 Million
Q3 2021 Nov 15, 2021	BUY	$35.66 - $42.94 $216,313 - $260,474	6,066 Added 4.26%	148,525 $5.44 Million
Q2 2021 Aug 13, 2021	BUY	$23.7 - $39.27 $532,373 - $882,122	22,463 Added 18.72%	142,459 $5.59 Million
Q1 2021 May 12, 2021	SELL	$27.01 - $36.8 $357,288 - $486,790	-13,228 Reduced 9.93%	119,996 $3.39 Million
Q4 2020 Feb 11, 2021	SELL	$27.51 - $34.36 $26,409 - $32,985	-960 Reduced 0.72%	133,224 $4.27 Million
Q3 2020 Nov 12, 2020	BUY	$25.8 - $34.61 $55,315 - $74,203	2,144 Added 1.62%	134,184 $4.34 Million
Q2 2020 Jul 31, 2020	BUY	$17.65 - $28.05 $380,481 - $604,673	21,557 Added 19.51%	132,040 $3.64 Million
Q1 2020 May 01, 2020	SELL	$15.19 - $29.51 $142,877 - $277,571	-9,406 Reduced 7.85%	110,483 $1.97 Million
Q4 2019 Feb 14, 2020	SELL	$17.17 - $25.95 $145,618 - $220,081	-8,481 Reduced 6.61%	119,889 $3.01 Million
Q3 2019 Nov 14, 2019	BUY	$17.84 - $22.69 $322,350 - $409,985	18,069 Added 16.38%	128,370 $2.29 Million
Q2 2019 Aug 14, 2019	SELL	$22.0 - $31.78 $149,314 - $215,690	-6,787 Reduced 5.8%	110,301 $2.43 Million
Q1 2019 May 14, 2019	BUY	$21.27 - $30.58 $382,838 - $550,409	17,999 Added 18.16%	117,088 $3.58 Million
Q4 2018 Feb 14, 2019	SELL	$23.09 - $37.69 $251,196 - $410,029	-10,879 Reduced 9.89%	99,089 $2.29 Million
Q3 2018 Nov 14, 2018	BUY	$26.55 - $34.38 $2.91 Million - $3.77 Million	109,537 Added 25414.62%	109,968 $3.54 Million
Q2 2018 Aug 14, 2018	SELL	$27.79 - $34.49 $60,609 - $75,222	-2,181 Reduced 83.5%	431 $13,000
Q1 2018 May 15, 2018	BUY	$28.87 - $41.13 $16,946 - $24,143	587 Added 28.99%	2,612 $78,000
Q4 2017 Feb 14, 2018	BUY	$27.41 - $39.42 $49,392 - $71,034	1,802 Added 808.07%	2,025 $80,000
Q3 2017 Nov 14, 2017	BUY	$22.15 - $27.5 $4,939 - $6,132	223	223 $6,000

Others Institutions Holding HCM

# of Institutions

Shares Held

6.99M

Call Options Held

6.2K

Put Options Held

1.1K

View Full List

About HUTCHMED (China) Ltd

Ticker HCM
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 172,955,008
Market Cap $2.39B
Description
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...

More about HCM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account